SyntheticMR AB announced that their next-generation imaging solution with isotropic 3D resolution, SyMRI 3D, has obtained approval in the EU and is now CE-Marked. With preparations in place, SyntheticMR eagerly anticipates the commercial launch of SyMRI 3D at the start of 2024. SyntheticMR's new 3D release is a next-generation imaging solution that is poised to revolutionize the field of medical imaging by introducing a myriad of innovative applications within SyMRI's post-processing solution.

This advanced SyMRI sequence introduces 3D resolution to quantitative values and tissue segmentations, ensuring the same level of precision in quantification as achieved with SyMRI's 2D imaging. SyMRI 3D enables precise volumetric estimations of brain regions, a technique commonly referred to as parcellation, which empowers clinicians to gain deeper insights into brain structure and function. Furthermore, the exceptional resolution provided by SyMRI 3D facilitates comprehensive lesion analysis, ensuring a more accurate and in-depth assessment of medical conditions.

The CE mark qualification for SyMRI 3D signifies a monumental stride for SyntheticMR, reaffirming its commitment to transforming medical imaging.